Homocysteine is a risk factor for reduced ejection fraction in children with myocarditis: a single-center study
Chengjun Zhang1, Xiuwen Ren2, Yufan Xu2
1Department of Pediatric, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Insights
Elevated homocysteine (HCY) is linked to reduced ejection fraction (EF) in children with myocarditis. This risk is higher in males and overweight pediatric patients, indicating HCY as a potential biomarker.
Area of Science:
- Cardiology
- Pediatric Medicine
- Biochemistry
Background:
- The association between homocysteine (HCY) and ejection fraction (EF) is established in adults with cardiovascular diseases.
- However, the relationship between HCY and EF in pediatric patients diagnosed with myocarditis is not well understood.
Purpose of the Study:
- To investigate the potential relationship between homocysteine levels and ejection fraction in pediatric patients suffering from myocarditis.
- To identify HCY as a possible risk factor for reduced EF in this specific pediatric population.
Main Methods:
- A cross-sectional study involving 164 pediatric myocarditis patients (aged 1-18 years) was conducted.
- Homocysteine levels and ejection fraction, measured by 3.0T cardiac magnetic resonance (CMR), were assessed.
- Statistical analyses included t-tests, binary logistic regression, and restricted cubic spline (RCS) modeling, with subgroup analyses by age, sex, and BMI.
Main Results:
- 31% of the pediatric patients exhibited reduced ejection fraction (EF < 55%).
- Elevated homocysteine levels showed a significant positive association with the risk of reduced EF (OR = 1.033, P = 0.034).
- Subgroup analyses revealed a stronger correlation between high HCY and reduced EF in males and in patients with a BMI ≥ 24 kg/m².
Conclusions:
- Elevated homocysteine levels represent a significant risk factor for reduced ejection fraction in pediatric patients with myocarditis.
- The association is particularly pronounced in male pediatric patients and those who are overweight.
- These findings highlight the potential role of HCY as a biomarker for assessing cardiac function in pediatric myocarditis.
Background:
The relationship between homocysteine (HCY) and ejection fraction (EF) has been demonstrated in diseases such as coronary artery disease, but the relationship between HCY and EF in pediatric patients with myocarditis remains unclear. The aim of this study was to investigate the relationship between HCY and EF in pediatric patients with myocarditis.
Methods:
This single-center cross-sectional study included 164 pediatric myocarditis patients aged 1-18 years, including 104 males and 60 females, at Anzhen Hospital (2023-2024) in Beijing. Patient demographic characteristics were collected, and blood tests were performed to assess HCY, routine blood tests, and markers of myocardial damage. EF was measured using 3.0T cardiac magnetic resonance (CMR), and patients were grouped using EF < 55% as the cutoff value. Statistical analyses were performed using t-tests, Binary logistic regression and Restrict cubic spline (RCS), and subgroup analyses [age, sex, body mass index (BMI)].
Results:
Of the 164 patients, 31% (n = 51) had EF values < 55%. High HCY concentration demonstrated a statistically positive relationship with the risk of occurrence of EF < 55% (OR = 1.033, P = 0.034). Subgroup analysis showed a stronger correlation in men (OR = 1.045, P = 0.016) and in those with a BMI ≥ 24 kg/m2 (OR = 1.083, P = 0.010). The RCS showed a non-significant trend of increasing EF < 55% (P > 0.05).
Conclusion:
The findings suggest that elevated HCY levels are a risk factor for EF < 55% in pediatric patients with myocarditis, especially in males and overweight individuals.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy


